TAK1 deficiency in dendritic cells inhibits adaptive immunity in SRBC-immunized C57BL/6 mice

Yao Pan1,2, Zhiming Lei1,2, Xuetao Wei1,2 and Weidong Hao1,2

1 Department of Toxicology, School of Public Health, Peking University, Beijing, China
2 Beijing Key Laboratory of Toxicological Research and Risk Assessment for Food Safety, Beijing, China

Keywords
dendritic cells; sheep red blood cells; T-cell dependent antigen response; transforming growth factor-β-activated kinase 1

Correspondence
W. Hao, Department of Toxicology, School of Public Health, Peking University Health Science Center, 38 Xue Yuan Road, Haidian District, Beijing 100191, China
Fax: +86 10 82802352
Tel: +86 10 82802352
E-mail: whao@bjmu.edu.cn

(Received 26 January 2016, revised 21 March 2016, accepted 29 March 2016)
doi:10.1002/2211-5463.12062

Dendritic cells (DCs) are important in the initiation of primary T-cell responses, while transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1) is a critical regulator of DC survival and homeostasis. This study evaluated the T-cell dependent antibody response (TDAR) to sheep red blood cells (SRBC) on a DC-specific TAK1-deficient mice model. The results showed that TAK1 deficiency in DCs significantly suppressed the humoral and cellular immune response in mice. DC-specific TAK1 deletion impaired splenic T-cell population and conventional DCs, abolished the cytokine production of splenic T cells and down-regulated some functional gene expression in the spleen. Collectively, this study suggests that TAK1 plays an essential role in the development of the humoral immune response.

Dendritic cells (DCs), a morphologically distinct form of antigen-presenting cell (APC), can capture, process, and present antigens in the form of peptides bound to major histocompatibility complex (MHC) molecules to activate T cells. It has been reported that in vivo antigen targeting to DCs induces strong T-cell priming and long-lived T cell help for antibody response [1,2]. DCs are famous for their role in activating and expanding T-helper (Th) cells, which in turn induce B-cell growth and immunoglobulin secretion [3]. Immunoglobulin class-switching also requires interaction between B cells and DCs [4]. Therefore, DCs play a central role in initiating and modulating humoral immunity.

Transforming growth factor-β (TGF-β)-activated kinase 1 (TAK1, encoded by Map3k7) belongs to the mitogen-activated protein kinase kinase kinase (MAP3K) family [5]. As a key regulator in inflammatory and immune signaling pathway, it can be activated by various stimuli [6,7]. TAK1 has an essential effect on promoting the survival, proliferation and function of adaptive immune cells T and B lymphocytes [6,8–11]. Besides, it also controls the homeostasis of innate immune cells such as DCs [12], NK cells [13] and neutrophils [14,15]. Sato et al. [6] reported that antigen-induced humoral immune responses to T-cell dependent and independent antigens were impaired in B cell-specific TAK1-deficient mice. Wang et al. [12] showed that deficiency of TAK1 in DCs caused apoptosis and depletion of DC subsets in lymphoid and nonlymphoid tissues and suppressed T-cell priming. But how DC-specific TAK1 deficiency affects T-cell dependent antibody response (TDAR) has not been reported.

Abbreviations
APC, antigen-presenting cell; DC, dendritic cell; DTH, delayed type hypersensitivity; IFN, interferon; IL, interleukin; MHC, major histocompatibility complex; PFC, plaque-forming cell; SRBC, sheep red blood cells; TAK1, transforming growth factor-β activated kinase 1; TDAR, T-cell dependent antibody response; Th cell, T-helper cells; WT, wild-type.
The TDAR depends on the cooperation and interaction of numerous immune cell types, including APCs, such as DCs, Th cells and B cells [16]. The TDAR is used as an immunotoxicity index, because it represents a comprehensive evaluation of immune function based on the assessment of various components of the immune system. Sheep red blood cell (SRBC) is a common T-cell dependent antigen to evaluate immune status in mice. After immunized with SRBC, this SRBC-specific IgM response in spleen can be measured by plaque-forming cell (PFC) assay [17]. This test is an IgM/complement dependent in vitro assay in mice, with SRBC as both the antigen and the target for complement mediated lysis. The SRBC PFC assay is considered the ‘gold standard’ for TDAR based on extensive intra- and inter-laboratory validation in mice and the fact that it has been utilized for over 35 years [18]. Although PFC assay is commonly used for assessing the potential immunotoxicity of xenobiotics [19–21], we used it in this study to evaluate the function of TAK1 in DCs on humoral immune response due to its integrated assessment capability and its sensitivity and stability.

The purpose of the study was to investigate the effect of DC-specific TAK1 deficiency on adaptive immune response in SRBC-immunized mice and to identify the impact of TAK1 in DCs on maintaining immune homeostasis and function. Here, we immunized the animals with SRBC and then performed functional assays including PFC assay, hemolysis test, and delayed type hypersensitivity (DTH) and quantified the antibody subsets in serum. Furthermore, splenic immune cell subpopulations, splenic T-cell cytokine production and splenic functional gene expressions were also detected.

Materials and methods

Experimental animals

Floxed Map3k7 (Map3k7\textsuperscript{fl/fl}) [8] and CD11c-Cre [22] mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). All mice are on C57BL/6 background. To delete TAK1 specifically in CD11c\textsuperscript{+} DCs, we crossed mice bearing loxP-flanked alleles of the Map3k7 gene with mice expressing Cre under the control of the CD11c promoter to generate Map3k7\textsuperscript{fl/fl} CD11c-Cre mice (called ‘Map3k7\textsuperscript{fl/fl} DC mice’ here-after). Wild-type (WT) controls were in the same genetic background and included Cre+ mice to account for Cre effects. Guinea pigs (250 g) were used for the preparation of complement for PFC assay and hemolysis test and they were purchased from Vital River Laboratory Animal Technology Co. Ltd (Beijing, China). All animals were healthy, housed in a barrier system (temperature: 20–26 °C; relative humidity: 40–70%) with a 12 h light/dark cycle. Water and standard diet were available ad libitum. The study was approved by the Animal Experimental Welfare & Ethical Inspection Committee of Peking University. Animal experiments and housing procedures were carried out in accordance with the laboratory animal administration rules of the Ministry of Science and Technology of the People’s Republic of China.

Chemicals and antibodies

Sheep red blood cells (SRBC) were purchased from Vital River Laboratory Animal Technology Co. Ltd. PE-Cy\textsuperscript{5} hamster anti-mouse CD3e, PE rat anti-mouse CD8a, FITC hamster anti-mouse CD11c and PE rat anti-mouse I-A/I-E were purchased from BD Pharmingen (San Diego, CA, USA). Anti-mouse CD4FITC and anti-human/mouse CD45R (B220) PE were obtained from eBioscience (San Diego, CA, USA). Mouse IgG, IgA, and IgM ELISA kits were purchased from Freemore Biotechnology Co. Ltd (Beijing, China). Guinea pig complement, Hanks balanced salt buffer (HBSS), SA buffer solution and Drabkin’s reagent were homemade.

Preparation of spleen cell suspensions

Each spleen isolated above was transferred to the 70 μm cell strainer in culture dishes containing 4 mL of cold HBSS and smashed the tissue with the plunger of a 1 mL syringe. Filtered the splenocyte suspensions through the two-layer carbasus on top of the tubes and washed twice in HBSS and centrifuged for 10 min at 230 g at room temperature. Splenocytes were resuspended in 10 mL HBSS. Cell numbers were determined for each splenocyte suspension by counting in a hemocytometer.

Plaque-forming cell assay

The Cunningham modification of Jerne and Nordin antibody plaque-forming cell assay was used [23–25] to determine IgM production by spleen cells. Mice were immunized on Day 1 with 0.2 mL of 2% (v/v) SRBC suspension in sterile saline via intraperitoneal injection. On day 5, the mice were killed and spleen cell suspensions were prepared as stated in the part of “Preparation of spleen cell suspension”. About 20 μL of spleen cell suspension in HBSS, 50 μL of 10% (v/v) SRBC in SA buffer solution and 500 μL of agar solution (0.5 g/100 ml in HBSS, pH 7.2–7.4) were mixed in a glass tube, and then poured onto slides. The slides were inverted on a special frame after the mixtures were solidified, and incubated at 37 °C for 1.5 h, then diluted guinea pig complement (1 : 10 diluted with SA buffer solution) was added to the slot between the slides and the bottom of the frame. The slides were incubated at 37 °C for another 1.5 h, then plaque production was
enumerated and the results were expressed as the number of PFC per 10^6 splenocytes.

**Hemolysis test**

Mice were immunized with SRBC as stated in the PFC assay section. The sera were obtained and assayed for HC50. One millilitre of SA buffer solution, 0.5 mL of 15% (v/v) SRBC, 1 mL of diluted guinea pig complement (1:10 diluted with SA buffer solution) and 3.3 mL of WT mice serum or 50 µL of Map3k7^dc^ mice serum were added into sample tubes and the blank control was the tube without serum. All tubes were kept in water bath for 15 min at 37 °C, and then the tubes were kept in ice bath to terminate the reaction. After centrifuged for 10 min at 890 g, 1 mL of supernatant was collected and added into 3 mL of Drabkin’s reagent, at the same time, 0.25 mL of 15% (v/v) SRBC and 3.75 mL of Drabkin’s reagent were mixed and placed for 10 min as positive control. The absorbance at 540 nm was detected using UV-2100 spectrophotometer (UNICO Instrument Co. Ltd, Shanghai, China), the HC50 value was got by the equation: 
\[ HC_{50} = \frac{(OD_{sample} - OD_{positive ~control}) \times dilution ~factor}{300} \]
(300 for WT mice and 20 for Map3k7^dc^ mice).

**Serum immunoglobulin isotypes quantification**

The animals were immunized with SRBC as stated in the PFC assay section. Blood for immunoglobulin isotypes quantification was collected into tubes without anticoagulant and centrifuged to obtain serum. Total IgG, IgM, and IgA titers in the serum of each animal were determined by ELISA kits. The assay procedures were in accordance with the descriptions in the manufacturer’s instructions. The absorbance (450 nm) of the contents of each well was determined using FLUOstar Omega multidetection microplate reader (BMG Labtech, Ortenberg, Germany).

**Delayed-type hypersensitivity to SRBC**

Mice were sensitized on Day 1 via intraperitoneal injection of 0.2 mL of 2% (v/v) SRBC in sterile saline. Five days later, the thickness of left rear footpad of each mouse was determined with a digital caliper (Mahr, Göttingen, Germany). Then, the left rear footpad was injected with 20 µL of 20% (v/v) SRBC by subcutaneous injection. After 24 h, the thickness of left rear footpad was measured again. Swelling was expressed by the difference between two measurements before and after injection of SRBC to left rear footpad.

**Flow cytometric analysis**

The animals were immunized with SRBC as stated in the PFC assay section and the spleen cell suspensions were prepared as stated in the part of “Preparation of spleen cell suspension”. The splenocytes were stained with combination of antibodies in 100 µL staining buffer (2% FBS in PBS) at 4 °C for 30 min in the dark. Excessive unreacted antibody was removed by washing the cells with staining buffer. Cells were resuspended at 10^6 cells per tube in 300 µL staining buffer and then analyzed on a FCS500-MPL flow cytometry (Beckman Coulter, Brea, CA, USA). A minimum of 20 000 events per sample was collected and analyzed for antigen expression.

**Stimulation of cytokine production and intracellular cytokine staining**

The animals were immunized with SRBC as stated in the PFC assay section and the spleen cell suspensions were prepared as stated in the part of “Preparation of spleen cell suspension”. The aliquots of 2 × 10^6 splenocytes were stimulated with cell stimulation cocktail (500×; ebioscience) for 4 h in the presence of Brefeldin A (1000×; ebioscience). The cells were stimulated in RPMI 1640 medium (Gibco, Shanghai, China) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, 2 mm l-glutamine and 50 µM 2-mercaptoethanol and incubated under a humidified atmosphere of 5% CO2/95% air at 37 °C. Different cell surface markers and intracellular cytokines were stained with cocktails of fluorescence-conjugated monoclonal antibodies according to the manufacturer’s protocols (ebioscience).

**Gene expression in spleen**

The animals were immunized with SRBC as stated in the PFC assay section. Total RNA was extracted from 1 × 10^7 splenocytes using TRIzol reagent (Transgen Biotech, Beijing, China) according to the manufacturer’s instruction. Total RNA (1 µg) was reverse transcribed with Oligo dT primer to cDNA using PrimeScript™ RT-PCR kit (Takara, Dalian, China). All real-time PCR primers were designed and synthesized by AuGCT DNA-SYN Biotechnology (Beijing, China). Real-time PCR primer sequences used are listed in Table 1. All real-time PCR reactions were carried out using SYBR® Premix Ex Taq™ II (TliRNaseH Plus) (Takara) and the IQ5 iCycler (Bio-Rad Laboratories, Hercules, CA, USA) according to manufacturer protocols. The relative gene expression was calculated using the delta-delta Ct (threshold cycle) method based on normalization to the reference gene Gapdh (glyceraldehyde-3-phosphate dehydrogenase).

**Statistical analysis**

Statistical analysis was performed using GRAPHPAD PRISM software (GraphPad, La Jolla, CA, USA). Data are expressed as mean ± standard deviation (SD). P values were calculated using Student’s t-test. Statistics with P value less than 0.05 were considered significant.
Results

The effect of TAK1 deficiency in DCs on adaptive immune response in SRBC-immunized mice

To confirm the successful generation of Map3k7\textsuperscript{DC} mice, we checked the TAK1 knockout efficiency in the mice. The results showed that the mRNA expression level of TAK1 was significantly decreased in splenic DCs (CD11c\textsuperscript{+} cells) but not CD4\textsuperscript{+} T cells compared to WT mice (Fig. 1). The deficiency of TAK1 in DCs induced markedly reduction in the number of lysate plaques (PFCs) counted in 10\textsuperscript{6} splenocytes and total serum hemolytic activity (HC50) (Fig. 2A,B). The dele-

The effect of DC-specific deletion of TAK1 on spleen cell subtyping in SRBC-immunized mice

The total number of splenocytes of Map3k7\textsuperscript{DC} mice was significantly lower than that of WT controls (Fig. 3A). Map3k7\textsuperscript{DC} mice had significantly reduced percentages of conventional DCs (cDCs, MHC-\textsuperscript{II}\textsuperscript{+} CD11c\textsuperscript{+}) and T cells (CD3\textsuperscript{+}), especially CD8\textsuperscript{+} T cells (cytotoxic T cells, Tc) (Fig. 3B,C). However, there was no dramatic change in B cells (B220\textsuperscript{+}) proportion between these two groups (Fig. 3B,C). TAK1 deficiency in DCs caused significant decrease in the counts of T cells, B cells, CD4\textsuperscript{+} T cells (Th cells), CD8\textsuperscript{+} T cells, cDCs in spleen (Fig. 3D).

The effect of TAK1 deletion in DCs on splenocyte gene expression in SRBC-immunized mice

Map3k7\textsuperscript{DC} mice showed markedly lower expression levels of several cytokines including IFN-\gamma, IL-2, IL-4 and IL-10 and reduced expression of transcription factors T-bet and GATA-3. In addition, expression of chemokine receptor CXCR4 was slightly down-regulated without statistical significance, but the expression of CCR7 was significantly reduced in Map3k7\textsuperscript{DC} mice.
We also detected the MHC molecules mRNA expression levels in the spleen, and both MHC-I and MHC-II molecules were dramatically down-regulated in Map3k7 DC mice (Fig. 5).

**Discussion**

This study was aimed to clarify how DC-specific TAK1-deficient mice responded to a T-cell dependent antigen-SRBC and to figure out its cellular and molecular mechanism. The results of this study showed that TAK1 deficiency in DCs suppressed SRBC-induced PFC response and DTH response and decreased the levels of HC50 and immunoglobulin isotypes in serum. Besides, the balance of immune cell subpopulations in spleen and the cytokines produced by splenic T cells were disrupted, while mRNA expression levels of several cytokines, transcription factors, chemokine receptor, and MHC molecules were also down-regulated in Map3k7 DC mice.

The adaptive immune response to the antigen includes both the cellular and humoral immunity and the mechanisms of which consist of antibody-producing B cells, various kinds of Th cells, killer T cells
and regulatory T cells. The humoral immune response induced by B cells is characterized by the specific antigen antibody reaction. The hemolysis test is an alternative to the PFC assay to measure the serum antibody level, which was first introduced in 1979 [26], and it is now endorsed by Ministry of Health of China as a first-line immune function test for evaluating the potential of health food to boost immunity [27]. PFC assays is the most common method to evaluate the humoral immunity mediated by SRBC, and the amount of serum antibodies is also an accepted biomarker of the humoral immune response [28]. DTH reaction is a kind of T-cell mediated immune response to SRBC and is usually used to assess the cellular immunity in mice [29]. In this study, compared with WT controls, PFC response was significantly suppressed and almost lost in Map3k7DC mice (Fig. 2A).

![Fig. 4.](image1)

**Fig. 4.** DC-specific deletion of TAK1 impaired the cytokines production of T cells in spleen. WT and Map3k7DC mice were immunized with SRBC as stated in the PFC assay section and the expression of IFN-γ and IL-4 in splenic CD4+ and CD8+ T cells was determined by intracellular cytokine staining after stimulation with PMA and ionomycin. (Left) Flow cytometry of splenic IFN-γ+CD4+, IFN-γ+CD8+, IL-4+CD4+ and IL-4+CD8+ populations. (Right) The proportion of these populations. The bars represented mean ± SD (n = 6). **p < 0.01 indicate significant changes compared to the WT group.

![Fig. 5.](image2)

**Fig. 5.** TAK1 deficiency in DCs downregulates the gene expression levels in spleen. WT and Map3k7DC mice were immunized with SRBC as stated in the PFC assay section and total RNA of spleens was analyzed for the expression levels of the indicated genes by real-time PCR. (A) Cytokines gene expression. (B) Transcription factors gene expression. (C) Chemokine receptors gene expression. (D) MHC molecules gene expression. The bars represented mean ± SD (n = 6). *p < 0.05, **p < 0.01 indicate significant changes compared to the WT group.

and regulatory T cells. The humoral immune response induced by B cells is characterized by the specific antigen antibody reaction. The hemolysis test is an alternative to the PFC assay to measure the serum antibody level, which was first introduced in 1979 [26], and it is now endorsed by Ministry of Health of China as a first-line immune function test for evaluating the potential of health food to boost immunity [27]. PFC assays is the most common method to evaluate the humoral immunity mediated by SRBC, and the amount of serum antibodies is also an accepted biomarker of the humoral immune response [28]. DTH reaction is a kind of T-cell mediated immune response to SRBC and is usually used to assess the cellular immunity in mice [29]. In this study, compared with WT controls, PFC response was significantly suppressed and almost lost in Map3k7DC mice (Fig. 2A). A dramatically reduced level of serum HC50 value and immunoglobulin isotypes—IgG, IgM, and IgA—were also found in DC-specific TAK1-deficient mice (Fig. 2B, D). This suggests an overall effect of TAK1 in DCs on antibody production, since variations attributed to the response to the immunogen and production of specific antibody should not explain a so

![Fig. 4.](image1)

**Fig. 4.** DC-specific deletion of TAK1 impaired the cytokines production of T cells in spleen. WT and Map3k7DC mice were immunized with SRBC as stated in the PFC assay section and the expression of IFN-γ and IL-4 in splenic CD4+ and CD8+ T cells was determined by intracellular cytokine staining after stimulation with PMA and ionomycin. (Left) Flow cytometry of splenic IFN-γ+CD4+, IFN-γ+CD8+, IL-4+CD4+ and IL-4+CD8+ populations. (Right) The proportion of these populations. The bars represented mean ± SD (n = 6). **p < 0.01 indicate significant changes compared to the WT group.

![Fig. 5.](image2)

**Fig. 5.** TAK1 deficiency in DCs downregulates the gene expression levels in spleen. WT and Map3k7DC mice were immunized with SRBC as stated in the PFC assay section and total RNA of spleens was analyzed for the expression levels of the indicated genes by real-time PCR. (A) Cytokines gene expression. (B) Transcription factors gene expression. (C) Chemokine receptors gene expression. (D) MHC molecules gene expression. The bars represented mean ± SD (n = 6). *p < 0.05, **p < 0.01 indicate significant changes compared to the WT group.
dramatic reduction in the global concentration of immunoglobulins. In accordance with the phenotype of other mice harboring cDC depletion [30], the antigen-specific antibodies generation after immunization was completely abolished. DTH reaction to SRBC in Map3k7^{ΔDC} mice was abrogated (Fig. 2C). This result is in agreement with our previous study that Map3k7^{ΔDC} mice failed to respond to 2, 4-dinitrofluorobenzene (DNFB)-induced contact hypersensitivity [31]. These results strongly suggest that TAK1 deficiency in DCs has an immunosuppressive effect in mice on both humoral and cellular immune function.

To further clarify the mechanisms that the deletion of TAK1 in DCs caused immunosuppression, total, helper, and cytotoxic T-cell percentages and counts, as well as total B-cell and CD11c^{+} DCs percentages and counts in the spleens were analyzed via flow cytometry. It was clear that TAK1 deficiency in DCs decreased the percentage of total T cells, Th cells, Tc cells, and cDCs, but the percentage of B cells remained intact (Fig. 3C). Owing to the decreased total splenic cell number (Fig. 3A), the cell counts of all subsets of the immune cells above were markedly reduced in Map3k7^{ΔDC} mice compared with those in WT controls (Fig. 3D). In nonimmunized Map3k7^{ΔDC} mice, it also exhibited reduced populations of CD4^{+} and CD8^{+} T cells and increased apoptosis of cDCs in spleen [12]. Collectively, TAK1 in DCs is essential for the homeostasis of both APCs and T-cell populations, but has no impact on B cells. SRBCs are nonreplicating T-cell dependent antigen that directly reach the spleen and induce the primary immune response there [32]. DCs and T cells both play a key role in T-dependent antibody formation. After T-cell dependent antigen exposure, DCs uptake the antigen and subsequently process and present it to activate antigen-specific Th cells. Then, Th cells activate B cells during cell–cell interaction and they also secrete several cytokines that induce B cells to proliferate and differentiate into plasma cells to produce antigen-specific antibodies [33–35]. Although Map3k7^{ΔDC} mice have intact splenic B cells proportion, they are lack of splenic cDCs and T cells to initiate the SRBC-induced humoral immune response. On the other hand, the number of B cells in the spleen of Map3k7^{ΔDC} mice was much less than that in WT mice (Fig. 3D), which means that much less B cells could function in the immune responses. Besides, Map3k7^{ΔDC} mice showed significantly increased percentages of macrophages and granulocytes in the spleen (Fig. 6). As DCs were much decreased in the spleen, macrophages, another kind of APCs, may be recruited to the spleen to function as the main source of APCs or to remove the cellular debris that accumulates after TAK1 was knockout in DCs. In nonimmunized Map3k7^{ΔDC} mice, it also exhibited expansion of granulocytes resulting from myeloid proliferation as a consequence of loss of TAK1 in DCs [12]. These might be possible explanations to why DC-specific TAK1-deficient mice are under immunosuppressed state.

Antigen-primed CD4^{+} T cells can be divided into at least two subsets based on the different cytokine they produced and these subsets are known as Th1 and Th2.
Th1 cells secrete IFN-γ and IL-2, which stimulates the maturation of DCs and improve the cellular immunity, and its transcription is depending on T-bet [16]. Th2 cells secrete IL-4, IL-5, IL-6, and IL-10 and its transcription factor is GATA3, which regulate the humoral immune response by inducing the proliferation and differentiation of B cells [36]. The intracellular cytokine immune response by inducing the proliferation and differentiation factor is GATA3, which regulate the humoral cells secrete IL-4, IL-5, IL-6, and IL-10 and its transcription is depending on T-bet [16]. Th2 maturation of DCs and improve the cellular immunity, in the spleen (Fig. 4). Along with this result, the real-time PCR results showed that DC-specific TAK1 deficiency significantly down-regulated the mRNA expression levels of Th1 and Th2 cytokines (Fig. 5A). Besides, the expression of transcription factors T-bet and GATA-3, the master regulators controlling Th1 and Th2 cells differentiation, were also down-regulated in the spleen of Map3k7DC mice (Fig. 5B), which indicated that deletion of TAK1 in DCs might inhibit the cytokines secretion by interfering with specific molecular programs to suppress Th-cell differentiation. In non-immunized Map3k7DC mice, the splenic T cells were impaired to produce IFN-γ and IL-2 upon acute polyclonal stimulation, indicative of altered function of T cells owing to TAK1 deletion in DCs [12]. In agreement with the phenotype of other mice harboring myeloid proliferation syndrome [37], the ability of T cells to produce IFN-γ was reduced. The impaired cytokine secretion function of T cells in spleen of Map3k7DC mice might attribute to the myeloid proliferation phenotype. And this further resulted in suppressing the SRBC-induced humoral immune response.

MHC molecules play a crucial role in the response of T cells to antigens, which known as antigen processing and presentation [16]. Our results showed that Map3k7DC mice significantly down-regulated mRNA expression levels of MHC I/II molecules (Fig. 5D), indicative the diminished ability of APCs to activate T cells after immunized with SRBC. Chemokines and their receptors constitute a molecular system to regulate immune cell migration for effective and robust immunity, while CCR7 and CXCR4 are two common chemokine receptors [16]. In this study, Map3k7DC mice showed significantly down-regulated mRNA expression levels of CCR7 after immunized with SRBC (Fig. 5C). It is evident that CCR7 axis in the T- and B-cell interactions is required to initiate effective high affinity humoral immune responses [38]. The data revealed that the deletion of TAK1 in DCs disrupted normal function of CCR7 to induce the humoral immune response after immunized with SRBC. Taken together, TAK1 specific deficiency in DCs might damage the key molecules in the initiation of SRBC-induced humoral immune responses.

In conclusion, our study demonstrated that TAK1 is critical for the development of humoral immune responses. Mechanistically, TAK1 is essential for survival of DCs, as well as the normal function and homeostasis of T-cell populations. Therefore, DC-specific targeting of TAK1 may be a feasible immunotherapy strategy.

 Acknowledgement

This study was supported by grant from the National Sciences Foundations of the People’s Republic of China [Grant No. 81273112].

Author contribution

YP and ZL conceived and designed the study and conducted the experiments. XW and WH contributed to the interpretation of results and the discussion. YP wrote the manuscript. All authors have read and approved the final version submitted for publication.

References

1 Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC and Steinman RM (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8 + T cell tolerance. J Exp Med 196, 1627–1638.

2 Boscardin SB (2006) Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 203, 599–606.

3 Banchereau J and Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392, 245–252.

4 Fayette J, Dubois B, Vandenabeele S, Bridon JM, Vanbervliet B, Durand I, Banchereau J, Caux C and Briere F (1997) Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. J Exp Med 185, 1909–1918.

5 Huang G, Shi LZ and Chi H (2009) Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination. Cytokine 48, 161–169.

6 Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, Matsumoto K, Takeuchi O and Akira S (2005) Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 6, 1087–1095.

7 Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M and Tanaka N (2005) TAK1, but not TAB 1 or TAB 2, plays an
TAK1 deletion in DC inhibits adaptive immunity

Y. Pan et al.

essential role in multiple signaling pathways in vivo. Genes Dev 19, 2668–2681.

8 Wan YY, Chi H, Xie M, Schneider MD and Flavell RA (2006) The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat Immunol 7, 851–858.

9 Sato S, Sanjo H, Tsujimura T, Ninomiya-Tsuji J, Yamamoto M, Kawai T, Takeuchi O and Akira S (2006) TAK1 is indispensable for development of T cells and prevention of colitis by the generation of regulatory T cells. Int Immunol 18, 1405–1411.

10 Liu HH, Xie M, Schneider MD and Chen ZJ (2006) Essential role of TAK1 in thymocyte development and activation. Proc Natl Acad Sci USA 103, 11677–11682.

11 Schuman J, Chen Y, Podd A, Yu M, Liu HH, Wen R, Chen ZJ and Wang D (2009) A critical role of TAK1 in B-cell receptor-mediated nuclear factor kappaB activation. Blood 113, 4566–4574.

12 Wang Y, Huang G, Vogel P, Neale G, Reizis B and Chi H (2012) Transforming growth factor beta-activated kinase 1 (TAK1)-dependent checkpoint in the survival of dendritic cells promotes immune homeostasis and function. Proc Natl Acad Sci USA 109, E343–E352.

13 Rajasekaran K, Chu H, Kumar P, Xiao Y, Tinguely M, Samarakoon A, Kim TW, Li X, Thakar MS and Zhang J (2011) Transforming growth factor-beta-activated kinase 1 regulates natural killer cell-mediated cytotoxicity and cytokine production. J Biol Chem 286, 31213–31224.

14 Ajibade AA, Wang Q, Cui J, Zou J, Xia X, Wang M, Tong Y, Hui W, Liu D and Su B (2012) TAK1 negatively regulates NF-kappaB and p38 MAP kinase activation in Gr-1+ CD11b+ neutrophils. Immunity 36, 43–54.

15 Lamotho B, Lai Y, Hur L, Orozco NM, Wang J, Campos AD, Xie M, Schneider MD, Lockworth CR and Jakacky J (2012) Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice. PLoS One 7, e51228.

16 Coico R, Sunshine G and Benjamini E (2003) Immunology-A Short Course, 5th edn Wiley-Liss, Hoboken, NJ.

17 White KL, Musgrove DL and Brown RD (2010) The sheep erythrocyte T-dependent antibody response (TDAR). Methods Mol Biol 598, 173–184.

18 Herzyk DJ and Holsapple M (2007) Immunotoxicity evaluation by immune function tests: focus on the T-dependent antibody response (TDAR) [Overview of a Workshop Session at the 45th Annual Meeting of the Society of Toxicology (SOT) March 5-9, 2006 San Diego, CAJ. J Immunotoxicol 4, 143–147.

19 US EPA (1998) Health Effects Test Guidelines, OPPTS 870.7800. Immunotoxicity pp. 1–11. http://www.epa.gov/opptsfrs/publications/OPPTS_Harmonized/870_HevalEffTest_Guidelines/Series/870-7800/pdf/
34 Lanzavecchia A (1985) Antigen-specific interaction between T and B cells. *Nature* **314**, 537–539.

35 Niiro H and Clark EA (2002) Regulation of B-cell fate by antigen-receptor signals. *Nat Rev Immunol* **2**, 945–956.

36 Coffman RL, Seymour BW, Lebman DA, Hiraki DD, Christiansen JA, Shrader B, Cherwinski HM, Savelkoul HF, Finkelman FD and Bond MW (1988) The role of helper T cell products in mouse B cell differentiation and isotype regulation. *Immunol Rev* **102**, 5–28.

37 Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, Lou J, Knobeloch KP, Gabriele L and Waring JF (1996) Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. *Cell* **87**, 307–317.

38 Comerford I, Harata-Lee Y, Bunting MD, Gregor C, Kara EE and McColl SR (2013) A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system. *Cytokine Growth Factor Rev* **24**, 269–283.